Introduction As chimeric antigen receptor T-cell therapies are becoming increasingly
available in the armamentarium of the hematologist, there is an emerging need to monitor …

Chimeric‐antigen‐receptor T cells directed against CD19 (CAR‐T) are emerging
hematological therapeutics with scarce data on its overall safety profile spectrum. To …

Chimeric antigen receptor (CAR) T cell therapy is approved in the United States for the
treatment of acute lymphocytic leukemia and aggressive B cell lymphomas. Multiple …

Hematotoxicity is the most common long-term adverse event (AE) after chimeric antigen
receptor T-cell (CAR T) therapy. However, patients who receive CAR T therapy in pivotal …

Chimeric antigen receptor (CAR)-T cell therapy is effective in the treatment of
refractory/relapsed (r/r) hematological malignancies (r/r B-cell lymphoblastic leukemia, B-cell …

Background Pivotal trials of chimeric antigen receptor T-cell (CAR-T) have identified
common toxicities but may have been underpowered to detect cardiovascular and …

Chimeric antigen receptor (CAR) T-cell therapy has greatly transformed the treatment and
prognosis of B-cell hematological malignancies. As CAR T-cell therapy continues to be more …

Chimeric antigen receptor T-cell (CAR-T) therapy has proven to be a very effective cancer
immunotherapy. Axicabtagene ciloleucel and tisagenlecleucel are the first-in-class anti …

Introduction Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising
treatment for relapsed or refractory large B-cell lymphoma (LBCL) with the Food and Drug …

Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies
that involves ex vivo genetic modification of T cells to incorporate an engineered CAR. After …